Zogenix, Inc. (ZGNX) Receives Average Rating of “Buy” from Brokerages

Shares of Zogenix, Inc. (NASDAQ:ZGNX) have been given a consensus rating of “Buy” by the eight brokerages that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $54.00.

Several research firms recently weighed in on ZGNX. BidaskClub lowered shares of Zogenix from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 8th. Zacks Investment Research raised shares of Zogenix from a “sell” rating to a “hold” rating in a research note on Wednesday, June 6th. Mizuho reissued a “buy” rating and set a $51.00 price objective on shares of Zogenix in a research note on Thursday, May 10th. Leerink Swann reaffirmed an “outperform” rating on shares of Zogenix in a research note on Sunday, March 4th. Finally, ValuEngine raised shares of Zogenix from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, May 2nd.

Zogenix stock traded down $0.20 during midday trading on Friday, hitting $44.80. 455,000 shares of the stock were exchanged, compared to its average volume of 550,595. Zogenix has a 52 week low of $10.05 and a 52 week high of $45.85. The firm has a market capitalization of $1.49 billion, a price-to-earnings ratio of -11.14 and a beta of 1.76.



Zogenix (NASDAQ:ZGNX) last released its quarterly earnings data on Wednesday, May 9th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.74) by ($0.13). During the same period last year, the company earned ($0.86) EPS. research analysts anticipate that Zogenix will post -3.89 EPS for the current fiscal year.

In other Zogenix news, EVP Gail M. Farfel sold 5,118 shares of Zogenix stock in a transaction that occurred on Tuesday, June 12th. The shares were sold at an average price of $45.00, for a total value of $230,310.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 4.60% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the business. SG Americas Securities LLC bought a new position in Zogenix in the first quarter valued at approximately $100,000. Meadow Creek Investment Management LLC bought a new stake in shares of Zogenix in the first quarter worth $192,000. Neuburgh Advisers LLC bought a new stake in shares of Zogenix in the first quarter worth $264,000. Tyers Asset Management LLC bought a new stake in shares of Zogenix in the first quarter worth $337,000. Finally, WINTON GROUP Ltd bought a new stake in shares of Zogenix in the first quarter worth $376,000.

Zogenix Company Profile

Zogenix, Inc, a pharmaceutical company, develops and commercializes therapies for the treatment of central nervous system disorders in the United States. Its lead product candidate is the ZX008, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome.

Analyst Recommendations for Zogenix (NASDAQ:ZGNX)

Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply